New Real-World Evidence from Personalized Trials Calls for Rethinking the Standard of Care for Non-Responders to Autoimmune Therapies

Personalized trials help patients achieve major reductions in joint flares and concomitant Rx in 17 weeks, while delivering $11k average autoimmune biologic and targeted therapy savings per non-responder annually. NEW YORK, June 1, 2023 /PRNewswire/ — Today Mymee Inc, a pioneer in personalized trials & care for patients with uncontrolled autoimmune and long COVID disease … Read more

Mymee’s Personalized Trial & Care Platform Helps Autoimmune Disease Patients Reverse Flares, New Research Shows

>85% of patients with moderate to severe symptoms at baseline achieved HRQoL improvements; severe symptoms saw largest improvements 76% were taking ≥ 1 immunosuppressant, >80% reported pain in joints & fatigue at baseline, 68% of patients enrolled in the study had comorbidities Peer-reviewed research published in RMD Open, leading journal for rheumatic and musculoskeletal diseases NEW … Read more